ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer

$ 19.00

4.9 (768) In stock

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

PDF) Emozioni scoperte: A COLLECTION OF AUTOBIOGRAPHICAL TEXTS BY ONCOLOGIC PATIENTS

PDF) A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines

PDF) Emozioni scoperte: A COLLECTION OF AUTOBIOGRAPHICAL TEXTS BY ONCOLOGIC PATIENTS

PDF) Critical Issues in Head and Neck Oncology

Frontiers Role of metastasectomy in the management of renal cell carcinoma

ASCO GU 2022: Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Sunitinibin the East Asian Subset of Patients With Advanced Renal Cell Carcinoma From the Phase 3 CLEAR Trial

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426

PDF) Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome